Pharvaris N.V. (NASDAQ: PHVS), a pioneering entity in the biotechnology industry, stands out in the healthcare sector with its innovative approach toward treating rare diseases such..
Ilika CEO Graeme Purdy explains how ORKA could accelerate Goliath's commercialisation through underwater defence applications while maintaining the company's long-term electric vehicle strategy...
Unite Group has exchanged contracts to sell the academy school at its Hawthorne House development in London for £40.7 million. The sale forms part of its..
Rio Tinto will invest US$1.9 billion to develop the Kangwinan bauxite project in Queensland, increasing Weipa Operations’ annual capacity to around 44 million tonnes. First production..
Edinburgh Investment Trust has declared a first interim dividend of 8.40 pence per ordinary share for the year ending 31 March 2027, up from 7.60 pence..
Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on 5 November 2026, highlighting technical evaluation work..
Ilika CEO Graeme Purdy explains how ORKA could accelerate Goliath's commercialisation through underwater defence applications while maintaining the company's long-term electric vehicle strategy...
Unite Group has exchanged contracts to sell the academy school at its Hawthorne House development in London for £40.7 million. The sale forms part of its asset disposal strategy, with proceeds initially earmarked for debt reduction...
Rio Tinto will invest US$1.9 billion to develop the Kangwinan bauxite project in Queensland, increasing Weipa Operations’ annual capacity to around 44 million tonnes. First production is targeted for 2029, with construction expected to support more than 1,300 jobs...
Edinburgh Investment Trust has declared a first interim dividend of 8.40 pence per ordinary share for the year ending 31 March 2027, up from 7.60 pence in 2026. The dividend is payable on 20 November 2026 to shareholders on the register on 6 November...
Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on 5 November 2026, highlighting technical evaluation work with the Christie Pathology Partnership and peer-reviewed research demonstrating test accuracy and reproducibility...
